Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI evaluation claim is directly supported by the provided FDA label excerpts, including the boxed warning, Section 5.1 monitoring guidance and age 24 years-or-younger risk statement, and pediatric use suicidality warning in Section 8.4, with no contradictions identified.
Category Scores
Accurate Statements
PAXIL increases the risk of suicidal thoughts and behaviors in pediatric/young adult patients.
Boxed Warning (WARNING: SUICIDAL THOUGHTS AND BEHAVIORS) and Warnings and Precautions 5.1 state increased risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies; Section 8.4 reiterates antidepressants increase risk in pediatric patients.
Monitoring is required, particularly in patients age 24 years and younger.
Warnings and Precautions 5.1: pooled analyses show higher incidence in antidepressant-treated patients age 24 years and younger than placebo; label instructs to closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months and at times of dosage changes.
Unsupported Statements
Contradictions
Important Omissions
The AI response does not explicitly restate that PAXIL is not approved for pediatric use, which is present in the provided label excerpts and is relevant to the pediatric component of the claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements align with the label’s boxed warning and monitoring language for suicidality in pediatric and young adult patients (age 24 years and younger). No contradictory or unsupported safety claims were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Moderate omission: failure to explicitly include the label statement that PAXIL is not approved for pediatric use (present in the provided excerpts).
Suggested Improvement
Explicitly include the label’s pediatric approval status ("PAXIL is not approved for use in pediatric patients") alongside the suicidality risk and monitoring language.